EC Number   |
Application |
Reference |
|---|
   2.8.2.30 | diagnostics |
heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a tumor regulator and a prognostic marker in breast cancer HER2+ patients for reduced relapse-free survival |
762063 |
| 2.8.2.30 | diagnostics |
specific HS sulfotransferases may serve as molecular markers and targets for cancer treatment |
761220 |
| 2.8.2.30 | drug development |
introduction of a single sulfate group into the heparin octasaccharide is sufficient for effective blocking of HSV-1 infection |
-, 690965 |
| 2.8.2.30 | medicine |
specific HS sulfotransferases may serve as molecular markers and targets for cancer treatment |
761220 |
| 2.8.2.30 | medicine |
the enzyme is a prognostic marker in breast cancer |
739207 |
| 2.8.2.30 | medicine |
the results provide evidence for specific epigenetic regulation of 3-OST genes resulting in altered heparan sulfate proteoglycans and point to a defect of heparan sulfate-3-O-sulfation as a factor in cancer progression |
703620 |
| 2.8.2.30 | pharmacology |
use of a chemoenzymatic synthetic approach to synthesize six 3-O-sulfated oligosaccharides, including three hexasaccharides and three octasaccharides. The synthesis is achieved by rearranging the enzymatic modification sequence to accommodate the substrate specificity of 3-O-sulfotransferase 3, analysis of the impact of 3-O-sulfation on the conformation of the pyranose ring of 2-O-sulfated iduronic acid using NMR spectroscopy, and on the correlation between ring conformation and anticoagulant activity. An octasaccharide interacts with antithrombin and displays anti factor Xa activity. The octasaccharide displays a faster clearance rate than fondaparinux, an FDA-approved pentasaccharide drug, in a rat model, making this octasaccharide a potential short-acting anticoagulant drug candidate that could reduce bleeding risk. The presence of the -GlcNS3S6S-IdoA2S- disaccharide unit is required for anticoagulant activity |
761349 |
| 2.8.2.30 | synthesis |
use of a chemoenzymatic synthetic approach to synthesize six 3-O-sulfated oligosaccharides, including three hexasaccharides and three octasaccharides. The synthesis is achieved by rearranging the enzymatic modification sequence to accommodate the substrate specificity of 3-O-sulfotransferase 3, analysis of the impact of 3-O-sulfation on the conformation of the pyranose ring of 2-O-sulfated iduronic acid using NMR spectroscopy, and on the correlation between ring conformation and anticoagulant activity. An octasaccharide interacts with antithrombin and displays anti factor Xa activity. The octasaccharide displays a faster clearance rate than fondaparinux, an FDA-approved pentasaccharide drug, in a rat model, making this octasaccharide a potential short-acting anticoagulant drug candidate that could reduce bleeding risk |
761349 |
